Clinical Trials Logo

Pancreatic Cancer clinical trials

View clinical trials related to Pancreatic Cancer.

Filter by:

NCT ID: NCT05875753 Recruiting - Pancreatic Cancer Clinical Trials

68Ga-FAPI-FS PET/CT and PET/MR in Pancreatic Cancer

Start date: June 1, 2022
Phase: Early Phase 1
Study type: Interventional

This is a preliminary study of 68Ga-FAPI-FS PET/CT or PET/MR in patients with confirmed or suspicious pancreatic cancer. The goal is to determine the safety, biodistribution, and tumor uptake of 68Ga-FAPI-FS.

NCT ID: NCT05872867 Recruiting - Colorectal Cancer Clinical Trials

Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90)

Start date: March 14, 2024
Phase: Phase 1
Study type: Interventional

The purpose of the present study is to determine the safety, tolerability, and efficacy of WM-A1-3389 in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancer (NSCLC).

NCT ID: NCT05864144 Recruiting - Breast Cancer Clinical Trials

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Start date: May 31, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.

NCT ID: NCT05861336 Recruiting - Pancreatic Cancer Clinical Trials

GEM+Nab-Paclitaxel Plus Losartan Followed by Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer

OVERPASS
Start date: June 14, 2023
Phase: Phase 2
Study type: Interventional

Single-arm, prospective, phase II study to evaluate safety and activity of an induction therapy with Gemcitabine (GEM) and nab-paclitaxel plus Losartan followed by Stereotactic Radiotherapy (SBRT) in patients affected by Locally Advanced Pancreatic Cancer (LAPC).

NCT ID: NCT05860374 Recruiting - Breast Cancer Clinical Trials

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors

Start date: March 2, 2023
Phase: Early Phase 1
Study type: Interventional

20 participants are expected to be enrolled for this open,Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with advanced solid tumors.

NCT ID: NCT05859750 Not yet recruiting - Pancreatic Cancer Clinical Trials

A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer

Start date: May 2023
Phase: Phase 2
Study type: Interventional

This study is a multicenter, open-label, phase II study to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activities of AK104,a PD-1/CTLA-4 bispecific antibody, in combination with gemcitabine and nab-paclitaxel as first-line therapy in subjects with advanced unresectable or metastatic pancreatic ductal adenocarcinoma.

NCT ID: NCT05848739 Recruiting - Ovarian Cancer Clinical Trials

A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

Start date: June 5, 2023
Phase: Phase 1
Study type: Interventional

This is an open-label, two-part, phase 1-2 study designed to determine the safety, tolerability, PK, pharmacodynamics (PD), and proof-of-concept efficacy of ST316 administered IV in subjects with selected advanced solid tumors likely to harbor abnormalities of the WNT/β-catenin signaling pathway. The study consists of two phases: a phase 1 dose escalation/regimen exploration phase and a phase 2 expansion phase.

NCT ID: NCT05842187 Recruiting - Pancreatic Cancer Clinical Trials

In Vitro Organoid Drug Sensitivity-Guided Treatment for Metastatic Pancreatic and Gastric Cancer

ODYSSEY
Start date: March 3, 2023
Phase: N/A
Study type: Interventional

The goal of this study is to evaluate the consistency between in vitro tumor organoid drug sensitivity and the therapeutic efficacy of in vivo drug treatment. Participants are required to provide one of fresh tumor tissues (including ascites, pleural effusion, biopsy tissues, palliative surgery specimens, etc.) for the purpose of culturing tumor organoids.

NCT ID: NCT05837767 Recruiting - Pancreatic Cancer Clinical Trials

A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue

Start date: July 24, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to find out whether lattice radiation therapy (LRT) is an effective radiation therapy technique when compared to standard stereotactic body radiation therapy (SBRT). The study will also study how the different radiation therapy techniques (LRT and SBRT) affect how many immune cells are able to attack and kill tumor cells (immune infiltration).

NCT ID: NCT05836870 Recruiting - Pancreatic Cancer Clinical Trials

Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer

Start date: July 18, 2023
Phase: Phase 3
Study type: Interventional

To learn if a supervised exercise program during chemotherapy treatments can help to improve outcomes in patients who have been diagnosed with pancreatic cancer